Recent News for UROV - Urovant Sciences Ltd.

Date Title
Jan 17 Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
Jan 8 Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 3 The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger
Jan 2 Company News For Jan 2, 2020
Jan 2 The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe
Jan 2 63 Biggest Movers From Tuesday
Dec 31 Urovant up 7% premarket on vibegron application
Dec 31 Urovant Sciences Trades Higher After Submitting Application For Overactive Bladder Treatment
Dec 31 4 Stocks To Watch For December 31, 2019
Dec 30 Urovant files U.S. application for vibegron for overactive bladder
Dec 30 Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Dec 30 Urovant secures $300M capital raise
Dec 30 Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo Dainippon Pharma
Dec 30 Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance
Dec 23 Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
Dec 16 Urovant Sciences Ltd. (UROV): Are Hedge Funds Right About This Stock?
Nov 12 Urovant Sciences files for $200M mixed shelf
Nov 9 Urovant Sciences Ltd. (UROV) CEO Keith Katkin on Q2 2019 Results - Earnings Call Transcript
Nov 5 Urovant Sciences EPS beats by $0.13
Nov 5 Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results
Oct 31 Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences
Oct 29 Urovant Sciences to Report 2019 Second Fiscal Quarter Financial Results
Oct 21 Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
Sep 24 Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Sep 6 Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

Back to the Main UROV Page...